

WCL/SEC/2025

24<sup>th</sup> September, 2025

To,

<b>BSE Ltd.</b> Listing Department, P. J. Towers, Dalal Street, Mumbai – 400 001. <b>(Scrip Code: Equity - 532144),</b> <b>(NCD – 960491 and 973309)</b>	<b>National Stock Exchange of India Ltd.</b> Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. <b>(Symbol: WELCORP, Series EQ)</b>
---	--

Dear Sir/ Madam,

**Sub: Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer Requests of Physical Shares.**

Ref.: a. Regulation 30 SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') read with SEBI operational circular bearing reference no SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 02, 2025.  
b. ISIN: INE191B01025

In continuation with our earlier Newspaper Publication submitted on July 11, 2025 and Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, extracts of the Newspaper Publications published in the in today's Financial Express (English), Kutchmitra and Kutchday (Gujarati), regarding Notice to Shareholders about opening of Special Window for Re-lodgement of transfer requests of Physical Shares in accordance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 02, 2025.

This is for your information and records.

Thanking you.

Yours faithfully,  
For **Welspun Corp Limited**

**Kamal Rathi**  
**Company Secretary and Compliance Officer**  
**ACS-18182**

Encl: As above

**Welspun Corp Limited**

Welspun House, 5th Floor, Kamala City, Senapati Bapat Marg, Lower Parel (W), Mumbai 400013. India

T: +91 22 6613 6000 / 2490 8000 | F: +91 22 2490 8020

E-mail: companysecretary\_wcl@welspun.com | Website: www.welspuncorp.com

Registered Address: Welspun City, Village Versamedi, Taluka Anjar, District Kutch, Gujarat 370110. India

T: +91 28 3666 2222 | F: +91 28 3627 9060

Corporate Identity Number: L27100GJ1995PLC025609

Sr no	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
37	7350	3	0.00	22,050	0.01	2,100	0 : 3	0
38	7500	26	0.03	195,000	0.10	2,100	0 : 26	0
39	7650	2	0.00	15,300	0.01	2,100	0 : 2	0
40	7800	10	0.01	78,000	0.04	2,100	0 : 10	0
41	7950	7	0.01	55,650	0.03	2,100	0 : 7	0
42	8100	10	0.01	81,000	0.04	2,100	0 : 10	0
43	8250	4	0.00	33,000	0.02	2,100	0 : 4	0
44	8400	36	0.04	302,400	0.16	2,100	0 : 36	0
45	8550	4	0.00	34,200	0.02	2,100	0 : 4	0
46	8700	2	0.00	17,400	0.01	2,100	0 : 2	0
47	8850	2	0.00	17,700	0.01	2,100	0 : 2	0
48	9000	23	0.03	207,000	0.11	2,100	0 : 23	0
49	9150	7	0.01	64,050	0.03	2,100	0 : 7	0
50	9300	2	0.00	18,600	0.01	2,100	0 : 2	0
51	9450	3	0.00	28,350	0.01	2,100	0 : 3	0
52	9600	3	0.00	28,800	0.02	2,100	0 : 3	0
53	9750	25	0.03	243,750	0.13	2,100	0 : 25	0
54	9900	10	0.01	99,000	0.05	2,100	0 : 10	0
55	Sino 12 to 54	-	0.00	-	0.00	2,100	4 : 933	8,400
56	Sino 2 to 54 (Allottees)	-	0.00	-	0.00	16	1 : 1	384
57	Sino 2 to 54 (Allottees)	-	0.00	-	0.00	1	2 : 3	16
<b>Total</b>		<b>87,849</b>	<b>100.00</b>	<b>191,488,200</b>	<b>100.00</b>			<b>1,000,000</b>

Please Note : 1 (One) lot of 2100 shares have been allocated to all the Applicants from Serial No. 12 to 54 in the ratio of 4 : 933 (All these categories have been moved at the end for easy reference)

Please Note : 16 additional Shares have been allocated to all the 24 Successful Allottees in Categories from Sino 2 to Sino 54 (I.e.excluding successful applicants from Category 2100 ) in the ratio of 1 : 1

Please Note : 1 additional share has been allocated to all the 24 Successful Allottees in Categories from Sino 2 to Sino 54 (I.e.excluding successful applicants from Category 2100 ) in the ratio of 2 : 3

#### C. Allotment to Non-Institutional Investors (above ₹10 lakhs) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (above ₹10 lakhs), who have bid at the Issue Price of ₹ 99 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 243,54795 times. The total number of Equity Shares allotted in this category is 2,000,000 Equity Shares to 952 successful applicants. The category-wise details of the Basis of Allotment are as under: (Sample)

Sr no	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
1	10200	45,311	96.19	462,172,200	94.88	2,100	133 : 6579	1,923,600
2	10350	398	0.84	4,119,300	0.85	2,100	4 : 199	16,800
3	10500	512	1.09	5,376,000	1.10	2,100	5 : 256	21,000
4	10650	103	0.22	1,096,950	0.23	2,100	2 : 103	1,200
5	10800	78	0.17	842,400	0.17	2,100	1 : 39	4,200
6	10950	90	0.19	985,500	0.20	2,100	1 : 45	4,200
7	11100	27	0.06	299,700	0.06	2,100	1 : 27	2,100
109	75000	1	0.00	75,000	0.02	2,100	0 : 1	0
110	80700	1	0.00	80,700	0.02	2,100	0 : 1	0
111	101100	2	0.00	202,200	0.04	2,100	0 : 2	0
112	101250	1	0.00	101,250	0.02	2,100	0 : 1	0
113	102000	5	0.01	510,000	0.10	2,100	0 : 5	0
114	150000	1	0.00	150,000	0.03	2,100	0 : 1	0
115	151650	1	0.00	151,650	0.03	2,100	0 : 1	0
116	201900	1	0.00	201,900	0.04	2,100	0 : 1	0
117	210000	1	0.00	210,000	0.04	2,100	0 : 1	0
118	252450	1	0.00	252,450	0.05	2,100	0 : 1	0
119	300000	1	0.00	300,000	0.06	2,100	0 : 1	0
120	Sino 14 to 119 (Allottees)	-	0.00	-	0.00	1	5 : 336	10,500
<b>Total</b>		<b>47,105</b>	<b>100.00</b>	<b>487,095,900</b>	<b>100.00</b>			<b>2,000,000</b>

Please Note : 1 (One) lot of 2100 shares have been allocated to All the Applicants from Serial No. 14 to 119 in the ratio of 5 : 336 (All these categories have been moved at the end for easy reference)

Please Note : 1 additional share has been allocated to all 952 Successful Allottees from all the Categories in the ratio of 100 : 119

#### D. Allotment to QIBs (After Rejections)

Allotment to QIBs, who have bid at the Issue Price of ₹ 99 per Equity Share or above, has been done on a proportionate basis in consultation with BSE. This category has been subscribed to the extent of 118,06100 times of Net QIB portion. As per the SEBI ICDR Regulations, Mutual Funds were allotted 5% of the Equity Shares of Net QIB portion available i.e. 90,000 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were allotted the remaining available Equity Share i.e. 1,710,000 Equity Shares on a proportionate basis. The total number of Equity Shares allotted in the QIB category is 1,800,000 Equity Shares, which were allotted to 43 successful Applicants. The category-wise details of the Basis of Allotment are as under:

Category	F/S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC/FII	Others	Total
QIB	681,867	92,934	100,502	-	-	221,221	703,476	<b>1,800,000</b>

#### E. Allotment to Anchor Investors (After Rejections)

The Company, in consultation with the BRLMs, have allocated 2,700,000 Equity Shares to 5 Anchor Investors (through 5 Applications) at the Anchor Investor Issue Price of ₹ 99 per Equity Share in accordance with the SEBI Regulations. This represents 60% of the QIB Portion.

Category	F/S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC/FII	Others	Total
ANCHOR	-	-	-	-	1,063,450	1,616,550	-	<b>2,700,000</b>

The Company on September 22, 2025 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and allotted the Equity Shares to various successful Bidders. The Allotment Advice-Intimation and/or notices have been dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Issue Account have been issued on September 22, 2025 and payment to non-Syndicate brokers have been issued on September 23, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on September 23, 2025 for credit into the respective beneficiary account subject to validation of the account details with the depositories concerned. The Company has filed the Listing application with BSE and NSE on September 23, 2025. The Company has received listing and trading approval from BSE and NSE and the trading will commence on or about September 24, 2025.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

#### INVESTORS PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Issue, KFin Technologies Limited at www.kfintech.com

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/sole Rider, Bid cum Application Form number, Rider DP ID, Client ID, PAN, date of submission of Bid-cum-Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:



KFin Technologies Limited

Selenium Building, Tower-B, Plot No. 31 & 32,

Financial District, Nanakramguda, Selenigamplly Hyderabad,

Rangareddi-500032, Telangana, India

Telephone: +91 40 26162222

E-mail: vms.ip@kfintech.com

Website: www.kfintech.com

Investor grievance e-mail: einward.ris@kfintech.com

Contact person: M. Murali Krishna

SEBI registration number: INR000000221

For VMS TMT LIMITED

On behalf of the Board of Directors

Sd/-

Bolya Vijay Amrabhai

Company Secretary and Compliance Officer

Date: September 23, 2025

Place: Ahmedabad

#### THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF VMS TMT LIMITED.

VMS TMT LIMITED has filed the Prospectus dated September 19, 2025 with RoC. The Prospectus is available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com – where equity shares are proposed to be listed, on the website of the Company i.e. www.vmstml.com and the website of the Book Running Lead Manager ("BRLM"), i.e. Arhant Capital Markets Limited at www.arhantcapital.com. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" on page 30 of the Prospectus.

The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities law. Accordingly, the Equity Shares are being offered and sold only outside the United States in "offshore transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.

#### HSBC MUTUAL FUND

##### NOTICE

Notice is hereby given that the Trustees of HSBC Mutual Fund have approved the declaration of dividends under the Income Distribution cum Capital Withdrawal (IDCW) option of the following scheme of HSBC Mutual Fund:

Sr. No.	Scheme/ Plan/ Option	Quantum of Dividend (in ₹ per unit)	NAV of the IDCW Option (as on September 22, 2025) (in ₹ per unit)
1.	HSBC Arbitrage Fund - Regular Plan - Quarterly IDCW Option	0.22	10,9979
2.	HSBC Arbitrage Fund - Direct Plan - Quarterly IDCW Option	0.25	11,1984

Record Date: September 26, 2025. Face Value: Rs 10 per unit

The above dividend is subject to availability of distributable surplus and may be lower to the extent of distributable surplus available on the record date. Pursuant to payment of dividend, the NAV of the IDCW option of the above-mentioned scheme/ plans will fall to the extent of dividend distribution and statutory levy, if any.


All the unitholders of the above scheme whose names appear on the register of unitholders as on the record date will be eligible to receive the dividend.

For & on behalf of HSBC Asset Management (India) Private Limited (Investment Manager to HSBC Mutual Fund)

Sd/-

Authorised Signatory

Mumbai, September 23, 2025



Asset Management

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

HSBC Asset Management (India) Private Limited, 9-11 floors, NESCO IT Park, Building no. 3, Western Express Highway, Goregaon (East), Mumbai—400 063, India.

Email: investor.line@mutualfund.hsbco.in, Website: www.assetmanagement.hsbco.in

Customer Service Number : 1800 200 2434 / 1800 4190 200

Issued by HSBC Asset Management (India) Private Limited

CIN-U74140MH2001C134220

#### Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary and Compliance Officer

Notified Office for the purpose of IFRS

ICSI Membership No. A71903

Place: Mumbai

Date: September 23, 2025

Notice to Shareholders

To update KYC and unpaid dividends

The Company takes various facilitation measures to reduce unpaid dividends, updating KYC and mandatorily from time to time to prevent the creation of unpaid/unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF).

The IEFP has also launched a 100-day Campaign, "Salakum Niveshak," starting from 29 July 2025 to 06 November 2025, for KYC and other relevant updates, and the same is being taken by the Company. The objective of this campaign is to facilitate shareholders for:

- Updating Know Your Customer (KYC) details, including Bank account mandates, registration, and Contact information - Email, Mobile number, Address, etc.
- Claiming unpaid/dividend amounts for any financial year(s) in order to prevent transfer to IEFP.

The Company has released communications to the concerned shareholders whose dividends remain unclaimed for seven consecutive years, the dividend amounts and corresponding base shares, if any, shall be transferred to the IEFP. We urge all shareholders to take prompt action during the campaign period to safeguard their entitlements and ensure compliance with statutory requirements.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary and Compliance Officer

Notified Office for the purpose of IFRS

ICSI Membership No. A71903

Place: Mumbai

Date: September 23, 2025

Notice to Shareholders

To update KYC and unpaid dividends

The Company takes various facilitation measures to reduce unpaid dividends, updating KYC and mandatorily from time to time to prevent the creation of unpaid/unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF).

The IEFP has also launched a 100-day Campaign, "Salakum Niveshak," starting from 29 July 2025 to 06 November 2025, for KYC and other relevant updates, and the same is being taken by the Company. The objective of this campaign is to facilitate shareholders for:

- Updating Know Your Customer (KYC) details, including Bank account mandates, registration, and Contact information - Email, Mobile number, Address, etc.
- Claiming unpaid/dividend amounts for any financial year(s) in order to prevent transfer to IEFP.

The Company has released communications to the concerned shareholders whose dividends remain unclaimed for seven consecutive years, the dividend amounts and corresponding base shares, if any, shall be transferred to the IEFP. We urge all shareholders to take prompt action during the campaign period to safeguard their entitlements and ensure compliance with statutory requirements.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary and Compliance Officer

Notified Office for the purpose of IFRS

ICSI Membership No. A71903

Place: Mumbai

Date: September 23, 2025

Notice to Shareholders



